2024-01-24 09:00:58 ET
Summary
- Sanofi acquires INBRX-101 from Inhibrx for $2.2 billion, targeting rare disease Alpha-1 Antitrypsin Deficiency (AATD).
- INBRX-101's monthly dosing offers a potential improvement over weekly treatments in AATD, with a novel AAT-Fc fusion approach.
- Financially, Sanofi is well-positioned with strong liquidity and assets to fund the acquisition, despite a notable debt load.
- Recommendation: Hold SNY stock; INBRX-101 acquisition is promising but Sanofi faces challenges in pipeline development and market performance.
At a Glance
Read the full article on Seeking Alpha
For further details see:
Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition